ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,881.63
      -0.43%
      US Tech 100
      20,449.60
      -0.85%
      Dow Jones
      42,544.22
      -0.07%
      Brent Oil
      73.855
      -1.33%
      Bitcoin
      94,208.56
      0.88%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Guardant Health Inc (GH) Quote

      Guardant Health Inc

      Guardant Health Inc (GH)

      Gamehost Inc
      30.55
      0.01
      (0.03%)
      Closed January 01 4:00PM
      Delayed by 15 minutes
      30.55
      0.00
      (0.00%)
      After Hours: 6:55PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      30.55
      Bid
      25.25
      Ask
      37.54
      Volume
      1,605,590
      30.1502 Day's Range 30.98
      15.81 52 Week Range 38.53
      Market Cap
      3.775B
      Previous Close
      30.54
      Open
      30.86
      Last Trade
      44867
      @
      30.55
      (average)
      Last Trade Time
      Financial Volume
      $ 49,009,182
      VWAP
      30.5241
      Average Volume (3m)
      1,769,550
      Shares Outstanding
      123,554,612
      Dividend Yield
      -
      PE Ratio
      -7.87
      Earnings Per Share (EPS)
      -3.88
      Revenue
      563.95M
      Net Profit
      -479.45M

      About Guardant Health Inc

      Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selectio... Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%. Show more

      Sector
      Medical Laboratories
      Industry
      Medical Laboratories
      Website
      www.guardanthealth.com
      Headquarters
      Dover, Delaware, USA
      Founded
      -
      Guardant Health Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker GH. The last closing price for Guardant Health was $30.54. Over the last year, Guardant Health shares have traded in a share price range of $ 15.81 to $ 38.53.

      Guardant Health currently has 123,554,612 shares outstanding. The market capitalization of Guardant Health is $3.77 billion. Guardant Health has a price to earnings ratio (PE ratio) of -7.87.

      Ask ADVFN Intelligence (AI)

      GH Latest News

      More News

      Meaningful Insights Biotech Analytics (MiBA) and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care

      Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Meaningful Insights Biotech Analytics (MiBA), an innovative healthcare technology company, today announced a unique...

      December 20 2024
      Business Wire

      Form 4 - Statement of changes in beneficial ownership of securities

      December 19 2024
      Edgar (US Regulatory)

      COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics

      COTA Inc., a leader in real-world data (RWD) and analytics for oncology, announces a new partnership with leading precision oncology company Guardant Health Inc. (Nasdaq: GH) that will allow...

      December 19 2024
      Business Wire

      Form 144 - Report of proposed sale of securities

      December 18 2024
      Edgar (US Regulatory)

      Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer

      Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration with Boehringer Ingelheim to pursue the regulatory approval and commercialization of the...

      December 18 2024
      Business Wire

      Form 4 - Statement of changes in beneficial ownership of securities

      December 16 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      December 16 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      December 16 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      December 16 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      December 16 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.55-1.7684887459831.131.84529.91132659430.94735717CS
      4-4.75-13.456090651635.338.5329.91148989633.98943555CS
      129.343.764705882421.2538.5320.14176955028.80722583CS
      261.65.5267702936128.9538.5320.14198605128.42000856CS
      523.9214.720240330526.6338.5315.81200697025.48466089CS
      156-70-69.6171059175100.55102.8515.81170258633.15133991CS
      260-46.63-60.417206530277.18181.0715.81142203454.44307848CS

      GH - Frequently Asked Questions (FAQ)

      What is the current Guardant Health share price?
      The current share price of Guardant Health is $ 30.55
      How many Guardant Health shares are in issue?
      Guardant Health has 123,554,612 shares in issue
      What is the market cap of Guardant Health?
      The market capitalisation of Guardant Health is USD 3.77B
      What is the 1 year trading range for Guardant Health share price?
      Guardant Health has traded in the range of $ 15.81 to $ 38.53 during the past year
      What is the PE ratio of Guardant Health?
      The price to earnings ratio of Guardant Health is -7.87
      What is the cash to sales ratio of Guardant Health?
      The cash to sales ratio of Guardant Health is 6.69
      What is the reporting currency for Guardant Health?
      Guardant Health reports financial results in USD
      What is the latest annual turnover for Guardant Health?
      The latest annual turnover of Guardant Health is USD 563.95M
      What is the latest annual profit for Guardant Health?
      The latest annual profit of Guardant Health is USD -479.45M
      What is the registered address of Guardant Health?
      The registered address for Guardant Health is 3500 S DUPONT HWY, KENT, DOVER, DELAWARE, 19901
      What is the Guardant Health website address?
      The website address for Guardant Health is www.guardanthealth.com
      Which industry sector does Guardant Health operate in?
      Guardant Health operates in the MEDICAL LABORATORIES sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      BDMDBaird Medical Investment Holdings Ltd
      $ 7.6699
      (630.47%)
      		89.74M
      APMAptorum Group Ltd
      $ 2.799
      (106.57%)
      		116.74M
      COEPCoeptis Therapeutics Holdings Inc
      $ 5.44
      (75.48%)
      		5.08M
      VRMEVerifyMe Inc
      $ 1.332
      (68.63%)
      		94.04M
      VEEETwin Vee PowerCats Company
      $ 0.55
      (53.59%)
      		5.62M
      WATTEnergous Corporation
      $ 1.00
      (-62.26%)
      		29.33M
      SGMOSangamo Therapeutics Inc
      $ 1.02
      (-56.41%)
      		44.56M
      INTZIntrusion Inc
      $ 3.07
      (-45.95%)
      		15.07M
      KZIAKazia Therapeutics Ltd
      $ 1.78
      (-42.58%)
      		708.99k
      TOIIWOncology Institute Inc
      $ 0.0052
      (-42.22%)
      		366.02k
      SVMHSRIVARU Holding Ltd
      $ 0.0423
      (26.65%)
      		794.74M
      XTIAXTI Aerospace Inc
      $ 0.0422
      (6.84%)
      		446.31M
      EYENEyenovia Inc
      $ 0.1474
      (30.10%)
      		412.83M
      CRKNCrown Electrokinetics Corporation
      $ 0.146899
      (5.91%)
      		402.05M
      ONCOOnconetix Inc
      $ 0.6479
      (48.26%)
      		270.47M

      GH Discussion

      View Posts
      Monksdream Monksdream 4 months ago
      GH buy the dip
      👍️0
      Monksdream Monksdream 5 months ago
      GH that awful Cathie has been a recent buyer
      👍️0
      x993231 x993231 5 months ago
      I'm in, $33 ish I like the potential. Short wise only 6% of float and 6 million shares only 200 million so I don't think we'll see a squeeze like ASTS has been doing.

      X. I just like to throw down a marker when I invest, I'm a long as in 80% of the time I hold shares for years and years many for decades.
      👍️0
      Monksdream Monksdream 7 months ago
      The American biotechnology company Guardant Health, which produces liquid biopsy tests to detect cancer from mutations and other modifications in blood samples,[1] was co-founded by Helmy Eltoukhy and AmirAli Talasaz during 2012–2013.[2][3] According to John Dorfman of the Pittsburgh Tribune-Review, Talasaz and Eltoukhy discovered a technique which "involves detecting and monitoring tumor fragments circulating in the patient's bloodstream", as an alternative to traditional tissue biopsies.[4] The duo met at Stanford University in 2002 and worked together at Illumina, until Talasaz left in 2012.[5]
      👍️0
      SubPenny0001 SubPenny0001 7 months ago
      I would add GH with EXAS both would score on the final outcome. FDA is expected to decide whether to approve Shield later this year.
      👍️0
      Trooperstocks Trooperstocks 8 months ago
      For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook. $GH
      👍️ 1 💪 1 💯 1
      Trooperstocks Trooperstocks 8 months ago
      $GH -Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer.
      👍️ 1 💪 1
      Trooperstocks Trooperstocks 8 months ago
      Guardant Health unveiled initial results from the ECLIPSE study validating the performance of the Shield test at the 2023 DDW meeting. The data served as the basis for Guardant Health’s submission of a premarket approval (PMA) application to the FDA, and the full study results have since been published in the March 2024 issue of The New England Journal of Medicine. An FDA Advisory Panel is scheduled to review the PMA application on May 23.

      The full abstracts for Guardant Health and a list of all abstracts being presented at the meeting will be available at the DDW website.

      For information and updates from the meeting, follow Guardant Health on LinkedIn, X (Twitter) and Facebook. $GH
      👍️ 1 💪 1 😍 1
      Trooperstocks Trooperstocks 8 months ago
      $GH Guardant Health Inc NASDAQ -Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
      May 16 2024 - 8:05AM


      Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Disease Week (DDW) meeting in Washington, DC, highlighting the value of the company’s Shield™ test in colorectal cancer (CRC) screening.

      “One in three eligible American adults have not been screened for CRC, in part because the currently available methods are unpleasant or inconvenient,” said AmirAli Talasaz, co-CEO of Guardant Health. “The data we will share at DDW underscores the important role that our Shield blood test can have in both improving screening rates and in detecting more colorectal cancer at an early stage, when it is most treatable. We look forward to sharing this important data at DDW.”
      👍️ 1 💯 1
      DewDiligence DewDiligence 2 years ago
      GH—(-34%/AH)—reports_results_of “Shield” ctDNA—(liquid biopsy)—diagnostic_for colorectal cancer:

      https://finance.yahoo.com/news/guardant-health-announces-positive-results-211600504.html

      https://finance.yahoo.com/news/1-guardant-dna-blood-test-220041937.html

      GH’s data aren’t bad, but they aren’t as good as those for EXAS’s Cologuard, which is based on a stool sample rather than a blood sample.

      EXAS is +24%/AH, adding about $2B(!) to its market cap.

      In #msg-168735158 (from May 2022), I said: Although GH says Shield is as good as EXAS’ Cologuard and MYNZ’s ColoAlert, I find it hard to believe that a blood test can be as sensitive for CRC (and precancerous lesions) as a stool-based test.I stand by that.
      👍️0
      jerseyboy jerseyboy 4 years ago
      I'm still feeling very good about owning this stock. There is no way I'll sell this before the next five years.
      👍️0
      jerseyboy jerseyboy 4 years ago
      I like the nice, gradual, consistent rise in the share price. I think there is no way to lose money here, and I think the gains will be very substantial over the next two to three years.
      👍️0
      jerseyboy jerseyboy 4 years ago
      So am I. This is THE company I have chosen in which to put my investment dollars that I feel is both a high-growth situation and one in which I am certain not to lose money.
      👍️0
      PR_12 PR_12 4 years ago
      2-3 years I'm thinking this is @ 3-5X current share price
      👍️0

      Your Recent History

      NASDAQ
      GH
      Guardant Health
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads